# Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Source: https://onco.cc/trials/nct06906341/  
OnCo record `nct06906341` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Relacorilant and Bevacizumab in ovarian cancer and endometrial cancer, run by Corcept Therapeutics, now recruiting.

## Summary

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers is a phase 2 interventional study registered as NCT06906341 by Corcept Therapeutics, with 270 participants planned, started 2025-04-11 and due to reach its primary completion in 2026-08. Interventions recorded: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2 and Bevacizumab 10 mg/kg.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06906341
- Phase: 2
- Setting: An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)
- Sponsor: Corcept Therapeutics
- Enrolled: 270

## Sources

- ClinicalTrials.gov NCT06906341: https://clinicaltrials.gov/study/NCT06906341

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Relacorilant](https://onco.cc/drugs/relacorilant/)
- companies: [Corcept Therapeutics](https://onco.cc/companies/corcept/)

---
JSON: https://onco.cc/api/v1/entities/nct06906341.json